Avinger

Executive Summary

Avinger, operating under the Lumivascular brand, is a privately held medical device company developing a proprietary catheter system that integrates real-time Optical Coherence Tomography (OCT) imaging to treat challenging chronic total occlusions (CTOs) in coronary and peripheral arteries. The company's mission is to improve procedural safety and efficacy by enabling direct visualization during atherectomy and crossing, replacing traditional reliance on angiography. Despite operating in a competitive landscape with established players like Abbott and Boston Scientific, Avinger's unique imaging integration has garnered interest, though the company faces challenges in scalability and reimbursement. With limited public funding history and no recent major milestones, Avinger's near-term outlook depends on its ability to secure regulatory approvals or strategic partnerships. The company's private status restricts visibility, but its technology holds potential for niche applications in complex vascular interventions.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for Next-Generation OCT Imaging Catheter60% success
• Q4 2026Strategic Partnership or Licensing Deal with a Major Cardiovascular Company40% success
• Q2 2026Publication of Clinical Data from Completed Trial Demonstrating Improved Outcomes50% success